Hao-Peng Sun

List of Publications by Year
in descending order

156 papers	4,257 citations	126907 33 h-index	155660 55 g-index
159 all docs	159 docs citations	159 times ranked	5799 citing authors

#	Article	IF	Citations
1	Overview of human 20 alpha-hydroxysteroid dehydrogenase (AKR1C1): Functions, regulation, and structural insights of inhibitors. Chemico-Biological Interactions, 2022, 351, 109746.	4.0	5
2	Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease. European Journal of Medicinal Chemistry, 2022, 232, 114170.	5.5	17
3	Design, synthesis, biological evaluation and molecular modeling of N-isobutyl-N-((2-(p-tolyloxymethyl)thiazol-4yl)methyl)benzo[d][1,3] dioxole-5-carboxamides as selective butyrylcholinesterase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2022, 61, 128602.	2.2	3
4	The Design and Optimization of Monomeric Multitarget Peptides for the Treatment of Multifactorial Diseases. Journal of Medicinal Chemistry, 2022, 65, 3685-3705.	6.4	1
5	A Practical and <scp>Highâ€Affinity</scp> Fluorescent Probe for Butyrylcholinesterase: A Good Strategy for Binding Affinity Characterization. Chinese Journal of Chemistry, 2022, 40, 1285-1292.	4.9	5
6	Elucidating the Novel Mechanism of Ligustrazine in Preventing Postoperative Peritoneal Adhesion Formation. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-30.	4.0	0
7	More than a Leaving Group: Nâ€Phenyltrifluoroacetimidate as a Remote Directing Group for Highly Î±â€Selective 1,2â€cis Glycosylation. Angewandte Chemie - International Edition, 2022, 61, .	13.8	12
8	Discovery of Resorcinol-Based Polycyclic Structures as Tyrosinase Inhibitors for Treatment of Parkinsonâ€™s Disease. ACS Chemical Neuroscience, 2022, 13, 81-96.	3.5	22
9	Therapeutic strategies of glioblastoma (GBM): The current advances in the molecular targets and bioactive small molecule compounds. Acta Pharmaceutica Sinica B, 2022, 12, 1781-1804.	12.0	27
10	<scp>2â€Diphenylphosphinoyl</scp>â€acetyl as a Remote Directing Group for the Highly Stereoselective Synthesis of <scp>Î²â€Glycosides</scp>. Chinese Journal of Chemistry, 2022, 40, 443-452.	4.9	18
11	Direct Synthesis of 2,6â€Dideoxyâ€Î²â€glycosides and Î²â€Rhamnosides with a Stereodirecting 2â€(Diphenylphosphinoyl)acetyl Group. Angewandte Chemie - International Edition, 2022, 61, .	13.8	9
12	A highly effective and stable butyrylcholinesterase inhibitor with multi-faceted neuroprotection and cognition improvement. European Journal of Medicinal Chemistry, 2022, 239, 114510.	5.5	5
13	AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma. Oncogene, 2022, 41, 3846-3858.	5.9	11
14	Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug Resistance. ACS Medicinal Chemistry Letters, 2022, 13, 1286-1294.	2.8	7
15	PROTACs suppression of GSK-3Î², a crucial kinase in neurodegenerative diseases. European Journal of Medicinal Chemistry, 2021, 210, 112949.	5.5	29
16	Synthesis and bio-evaluation of a novel selective butyrylcholinesterase inhibitor discovered through structure-based virtual screening. International Journal of Biological Macromolecules, 2021, 166, 1352-1364.	7.5	5
17	Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2021, 30, 115940.	3.0	14
18	STING, a promising target for small molecular immune modulator: A review. European Journal of Medicinal Chemistry, 2021, 211, 113113.	5.5	37

#	Article	IF	Citations
19	Recent research progress of Uncaria spp. based on alkaloids: phytochemistry, pharmacology and structural chemistry. European Journal of Medicinal Chemistry, 2021, 210, 112960.	5.5	45
20	Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism. Medicinal Research Reviews, 2021, 41, 858-901.	10.5	45
21	Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. Bioorganic and Medicinal Chemistry Letters, 2021, 34, 127756.	2.2	7
22	In silico approaches using pharmacophore model combined with molecular docking for discovery of novel ULK1 inhibitors. Future Medicinal Chemistry, 2021, 13, 341-361.	2.3	6
23	AchievingÂeffective and selective CK1 inhibitors through structure modification. Future Medicinal Chemistry, 2021, 13, 505-528.	2.3	8
24	Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection. Journal of Medicinal Chemistry, 2021, 64, 6856-6876.	6.4	38
25	Design, Bioâ€evaluation and Molecular Dynamics Simulation of Novel GSKâ€3Î² Inhibitors. Molecular Informatics, 2021, 40, e2060031.	2.5	2
26	Synthesis and activity of miconazole derivatives as dual BChE/IDO1 inhibitors for the treatment of Alzheimer's disease. Future Medicinal Chemistry, 2021, 13, 1105-1125.	2.3	1
27	Strategies for Structural Modification of Small Molecules to Improve Bloodâ€“Brain Barrier Penetration: A Recent Perspective. Journal of Medicinal Chemistry, 2021, 64, 13152-13173.	6.4	69
28	Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010â€“2020). European Journal of Medicinal Chemistry, 2021, 226, 113874.	5.5	25
29	Computational design of binder as the LC3-p62 proteinâ€protein interaction. Bioorganic Chemistry, 2021, 115, 105241.	4.1	11
30	Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3Î² inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine. European Journal of Medicinal Chemistry, 2021, 223, 113663.	5.5	3
31	Degradation of proteins by PROTACs and other strategies. Acta Pharmaceutica Sinica B, 2020, 10, 207-238.	12.0	196
32	Reasonably activating Nrf2: A long-term, effective and controllable strategy for neurodegenerative diseases. European Journal of Medicinal Chemistry, 2020, 185, 111862.	5.5	27
33	Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. Colloids and Surfaces B: Biointerfaces, 2020, 188, 110795.	5.0	30
34	Design, synthesis, inÂvitro and inÂvivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 330-343.	5.2	19
35	Design and evaluation of Nrf2 activators with 1,3,4-oxa/thiadiazole core as neuro-protective agents against oxidative stress in PC-12 cells. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126853.	2.2	4
36	Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimerâ€™s disease. European Journal of Medicinal Chemistry, 2020, 207, 112751.	5.5	15

#	Article	IF	Citations
37	Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 10030-10044.	6.4	48
38	Overview of AKR1C3: Inhibitor Achievements and Disease Insights. Journal of Medicinal Chemistry, 2020, 63, 11305-11329.	6.4	47
39	Discovery of a Selective 6-Hydroxy-1, 4-Diazepan-2-one Containing Butyrylcholinesterase Inhibitor by Virtual Screening and MM-GBSA Rescoring. Dose-Response, 2020, 18, 155932582093852.	1.6	2
40	Small molecular Nrf2 inhibitors as chemosensitizers for cancer therapy. Future Medicinal Chemistry, 2020, 12, 243-267.	2.3	21
41	Design, Synthesis, and Evaluation of Acetylcholinesterase and Butyrylcholinesterase Dual-Target Inhibitors against Alzheimerâ€™s Diseases. Molecules, 2020, 25, 489.	3.8	12
42	Design, synthesis and biological evaluation of novel carboline-cinnamic acid hybrids as multifunctional agents for treatment of Alzheimerâ€™s disease. Bioorganic Chemistry, 2020, 99, 103844.	4.1	15
43	p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators. Journal of Medicinal Chemistry, 2020, 63, 10135-10157.	6.4	26
44	Small molecule modulators targeting protein kinase CK1 and CK2. European Journal of Medicinal Chemistry, 2019, 181, 111581.	5.5	38
45	Design, synthesis, biological evaluation, and molecular modeling studies of quinoline-ferulic acid hybrids as cholinesterase inhibitors. Bioorganic Chemistry, 2019, 93, 103310.	4.1	33
46	Discovery, molecular dynamic simulation and biological evaluation of structurally diverse cholinesterase inhibitors with new scaffold through shape-based pharmacophore virtual screening. Bioorganic Chemistry, 2019, 92, 103294.	4.1	12
47	A Mild and Direct C(sp‹sub›3‹/sub›)â€“S Cross-Coupling of Oxindoles with Thiols: Synthesis of Unsymmetrical 3-Thiooxindoles. Journal of Organic Chemistry, 2019, 84, 14342-14348.	3.2	12
48	Bioactivity-based analysis and chemical characterization of hypoglycemic and antioxidant components from Artemisia argyi. Bioorganic Chemistry, 2019, 92, 103268.	4.1	31
49	A facile and efficient [4 + 2] annulation reaction of sulfur ylides: access to N-fused benzimidazoles. Organic Chemistry Frontiers, 2019, 6, 205-208.	4.5	11
50	Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. Bioorganic and Medicinal Chemistry, 2019, 27, 114930.	3.0	11
51	Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms. Journal of Medicinal Chemistry, 2019, 62, 8881-8914.	6.4	164
52	Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation. European Journal of Medicinal Chemistry, 2019, 174, 159-180.	5.5	37
53	Characterization, quantitation, similarity evaluation and combination with Na+,K+-ATPase of cardiac glycosides from Streblus asper. Bioorganic Chemistry, 2019, 87, 265-275.	4.1	12
54	Expansion of the scaffold diversity for the development of highly selective butyrylcholinesterase (BChE) inhibitors: Discovery of new hits through the pharmacophore model generation, virtual screening and molecular dynamics simulation. Bioorganic Chemistry, 2019, 85, 117-127.	4.1	24

#	Article	IF	Citations
55	CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. European Journal of Medicinal Chemistry, 2019, 164, 77-91.	5.5	49
56	Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. European Journal of Medicinal Chemistry, 2019, 161, 378-398.	5.5	66
57	Small molecule KDM4s inhibitors as anti-cancer agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 777-793.	5.2	22
58	Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry, 2018, 26, 1665-1674.	3.0	27
59	Synthesis, pharmacology and molecular docking on multifunctional tacrine-ferulic acid hybrids as cholinesterase inhibitors against Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 496-506.	5.2	52
60	Dual GSK-3Î²/AChE Inhibitors as a New Strategy for Multitargeting Anti-Alzheimerâ€™s Disease Drug Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 171-176.	2.8	76
61	Synthesis and bioevaluation of new tacrine-cinnamic acid hybrids as cholinesterase inhibitors against Alzheimerâ€™s disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 290-302.	5.2	31
62	Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429. Cell Death and Disease, 2018, 8, e3178-e3178.	6.3	22
63	Design of Small Molecule Autophagy Modulators: A Promising Druggable Strategy. Journal of Medicinal Chemistry, 2018, 61, 4656-4687.	6.4	25
64	The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery. Current Pharmaceutical Design, 2018, 24, 3424-3439.	1.9	35
65	A convenient cyclopropanation process of oxindoles via bromoethylsulfonium salt. Tetrahedron, 2018, 74, 6809-6814.	1.9	7
66	Convenient Method of Synthesizing Aryloxyalkyl Esters from Phenolic Esters Using Halogenated Alcohols. Molecules, 2018, 23, 1715.	3.8	3
67	Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2018, 158, 463-477.	5.5	136
68	The recent progress of isoxazole in medicinal chemistry. Bioorganic and Medicinal Chemistry, 2018, 26, 3065-3075.	3.0	233
69	Chemical Constituents of the Seed Cake of Camellia oleifera and Their Antioxidant and Antimelanogenic Activities. Chemistry and Biodiversity, 2018, 15, e1800137.	2.1	21
70	Anti-angiogenic and anticancer effects of baicalein derivatives based on transgenic zebrafish model. Bioorganic and Medicinal Chemistry, 2018, 26, 4481-4492.	3.0	20
71	Design, synthesis and evaluation of novel bivalent Î² -carboline derivatives as multifunctional agents for the treatment of Alzheimer's disease. Bioorganic and Medicinal Chemistry, 2018, 26, 3812-3824.	3.0	24
72	Recent Advances in the Discovery of HIF-1Î±-p300/CBP Inhibitors as Anti-Cancer Agents. Mini-Reviews in Medicinal Chemistry, 2018, 18, 296-309.	2.4	23

#	Article	IF	Citations
73	Identification by shape-based virtual screening and evaluation of new tyrosinase inhibitors. PeerJ, 2018, 6, e4206.	2.0	13
74	Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structure-based virtual screening. RSC Advances, 2017, 7, 3429-3438.	3.6	55
75	Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). Expert Opinion on Therapeutic Patents, 2017, 27, 763-785.	5.0	36
76	Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease. European Journal of Medicinal Chemistry, 2017, 132, 294-309.	5.5	229
77	Gamma secretase inhibitors: a patent review (2013 - 2015). Expert Opinion on Therapeutic Patents, 2017, 27, 851-866.	5.0	19
78	Design, synthesis, in vitro and in vivo evaluation of tacrineâ€“cinnamic acid hybrids as multi-target acetyl- and butyrylcholinesterase inhibitors against Alzheimer's disease. RSC Advances, 2017, 7, 33851-33867.	3.6	35
79	Current Development of ROS-Modulating Agents as Novel Antitumor Therapy. Current Cancer Drug Targets, 2017, 17, 122-136.	1.6	36
80	G9a - An Appealing Antineoplastic Target. Current Cancer Drug Targets, 2017, 17, 555-568.	1.6	22
81	Therapeutic Agents in Alzheimer's Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core. Current Topics in Medicinal Chemistry, 2017, 17, 3000-3016.	2.1	31
82	Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors. PeerJ, 2016, 4, e2140.	2.0	18
83	Discovery and optimization of new benzofuran derivatives against p53-independent malignant cancer cells through inhibition of HIF-1 pathway. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2713-2718.	2.2	13
84	Bioorganic and Medicinal Chemistry, 2016, 24, 2423-2432.	3.0	6
85	Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5. European Journal of Medicinal Chemistry, 2016, 118, 1-8.	5.5	38
86	Betulinic acid acetate, an antiproliferative natural product, suppresses client proteins of heat shock protein pathways through a CDC37-binding mechanism. RSC Advances, 2016, 6, 42537-42544.	3.6	2
87	CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells. Scientific Reports, 2016, 6, 19004.	3.3	8
88	Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. Bioorganic and Medicinal Chemistry, 2016, 24, 1006-1013.	3.0	25
89	Microwave-assisted copper- and palladium-catalyzed sonogashira-type coupling of aryl bromides and iodides with trimethylsilylacetylene. Tetrahedron Letters, 2016, 57, 1100-1103.	1.4	12
90	NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget, 2016, 7, 73593-73606.	1.8	101

#	Article	IF	Citations
91	Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity. Current Topics in Medicinal Chemistry, 2016, 16, 1843-1854.	2.1	9
92	Discovery of novel inhibitors disrupting HIF-1Î±/von Hippelâ€“Lindau interaction through shape-based screening and cascade docking. PeerJ, 2016, 4, e2757.	2.0	8
93	Discovery of NAD(P)H:quinone oxidoreductase 1 (NQO1) inhibitors with novel chemical scaffolds by shape-based virtual screening combined with cascade docking. RSC Advances, 2015, 5, 49471-49479.	3.6	8
94	Synthesis and evaluation of (Â±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1). Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1244-1248.	2.2	35
95	Discovery and identification of Cdc37-derived peptides targeting the Hsp90â€“Cdc37 proteinâ€“protein interaction. RSC Advances, 2015, 5, 96138-96145.	3.6	20
96	Palladium(II)-Catalyzed Câ€“H Bond Activation/Câ€“C Coupling/Intramolecular Tsujiâ€“Trost Reaction Cascade: Facile Access to 2H-Pyranonaphthoquinones. Organic Letters, 2015, 17, 3410-3413.	4.6	20
97	Discovery and Modification of in Vivo Active Nrf2 Activators with 1,2,4-Oxadiazole Core: Hits Identification and Structureâ€“Activity Relationship Study. Journal of Medicinal Chemistry, 2015, 58, 5419-5436.	6.4	48
98	Discovery of new acetylcholinesterase inhibitors with small core structures through shape-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3442-3446.	2.2	24
99	Novel natural-product-like caged xanthones with improved druglike properties and in vivo antitumor potency. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2584-2588.	2.2	21
100	A sensitive colorimetric strategy for monitoring cerebral Î²-amyloid peptides in AD based on dual-functionalized gold nanoplasmonic particles. Chemical Communications, 2015, 51, 8880-8883.	4.1	22
101	Identification of novel JMJD2A inhibitor scaffold using shape and electrostatic similarity search combined with docking method and MM-GBSA approach. RSC Advances, 2015, 5, 82936-82946.	3.6	6
102	Discovery of new scaffolds from approved drugs as acetylcholinesterase inhibitors. RSC Advances, 2015, 5, 90288-90294.	3.6	17
103	Structureâ€“Activity and Structureâ€“Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1â€“Nrf2 Proteinâ€“Protein Interaction Inhibitor. Journal of Medicinal Chemistry, 2015, 58, 6410-6421.	6.4	76
104	Novel 5-carboxy-8-HQ based histone demethylase JMJD2A inhibitors: Introduction of an additional carboxyl group at the C-2 position of quinoline. European Journal of Medicinal Chemistry, 2015, 105, 145-155.	5.5	18
105	Affinity-Based Fluorescence Polarization Assay for High-Throughput Screening of Prolyl Hydroxylase 2 Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 1236-1240.	2.8	22
106	NbCl5 mediated biomimetic cascade reaction: efficient and scalable one-pot synthesis of dunnione and nor-Î²-lapachone. Tetrahedron Letters, 2015, 56, 397-400.	1.4	5
107	Novel approach to stereoselective synthesis of (E)/(Z)-(N-acyl-oxazolidinone)-eneglycinates. Research on Chemical Intermediates, 2015, 41, 749-760.	2.7	2
108	Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shapeâ€Based Similarity Screening. Molecular Informatics, 2014, 33, 293-306.	2.5	4

#	Article	IF	Citations
109	Discovery of novel covalent proteasome inhibitors through a combination of pharmacophore screening, covalent docking, and molecular dynamics simulations. Journal of Molecular Modeling, 2014, 20, 2515.	1.8	15
110	Hybrids of the Benzofuran Core from Natural Products and the 2,4â€Dihydroxyâ€5â€isopropylbenzene Fragment as Potent Hsp90 Inhibitors: Design, Synthesis and Bioevaluation. Molecular Informatics, 2014, 33, 495-502.	2.5	1
111	Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. European Journal of Medicinal Chemistry, 2014, 79, 399-412.	5.5	36
112	2-Substituted 3-methylnaphtho[1,2-b]furan-4,5-diones as novel L-shaped ortho-quinone substrates for NAD(P)H:quinone oxidoreductase (NQO1). European Journal of Medicinal Chemistry, 2014, 82, 56-67.	5.5	46
113	Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I). European Journal of Medicinal Chemistry, 2014, 81, 89-94.	5.5	16
114	Lewis acid mediated highly regioselective intramolecular cyclization for the synthesis of Î²-lapachone. Tetrahedron Letters, 2014, 55, 1475-1478.	1.4	17
115	Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1557-1561.	2.2	6
116	Novel proteinâ€“protein interaction inhibitor of Nrf2â€“Keap1 discovered by structure-based virtual screening. MedChemComm, 2014, 5, 93-98.	3.4	55
117	Investigation of the intermolecular recognition mechanism between the E3 ubiquitin ligase Keap1 and substrate based on multiple substrates analysis. Journal of Computer-Aided Molecular Design, 2014, 28, 1233-1245.	2.9	25
118	Microwave-assisted transition-metal-free intramolecular Ullmann-type O-arylation in water for the synthesis of xanthones and azaxanthones. Tetrahedron Letters, 2014, 55, 4883-4887.	1.4	15
119	Discovery of Potent Keap1â€“Nrf2 Proteinâ€“Protein Interaction Inhibitor Based on Molecular Binding Determinants Analysis. Journal of Medicinal Chemistry, 2014, 57, 2736-2745.	6.4	193
120	Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents. Current Medicinal Chemistry, 2014, 21, 3893-3917.	2.4	21
121	Insights into Targeting NEMO for Pharmacological Regulation. Current Drug Targets, 2014, 15, 874-887.	2.1	1
122	Discovery of Novel CK2 Leads by Cross-Docking Based Virtual Screening. Medicinal Chemistry, 2014, 10, 628-639.	1.5	2
123	The Discovery of Novel Histone Lysine Methyltransferase G9a Inhibitors (Part 1): Molecular Design Based on a Series of Substituted 2,4-Diamino-7- aminoalkoxyquinazoline by Molecular-Docking-Guided 3D Quantitative Structure-Activity Relationship Studies. Medicinal Chemistry, 2014, 10, 426-440.	1.5	4
124	Discovery of Aroyl Piperazine Derivatives as I_{Kr} & I_{Ks} Dual Inhibitors for Cardiac Arrhythmia Treatment. Medicinal Chemistry, 2014, 10, 497-505.	1.5	0
125	Garcinia Xanthones as Orally Active Antitumor Agents. Journal of Medicinal Chemistry, 2013, 56, 276-292.	6.4	55
126	Synthesis and bioevaluation of a series of Î±-pyrone derivatives asÂpotent activators of Nrf2/ARE pathway (part I). European Journal of Medicinal Chemistry, 2013, 66, 364-371.	5.5	27

#	Article	IF	Citations
127	Novel IKKÎ² inhibitors discovery based on the co-crystal structure by using binding-conformation-based and ligand-based method. European Journal of Medicinal Chemistry, 2013, 63, 269-278.	5.5	9
128	Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors. Bioorganic and Medicinal Chemistry, 2013, 21, 6466-6476.	3.0	23
129	Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification. Journal of Chemical Information and Modeling, 2013, 53, 2093-2102.	5.4	18
130	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). Bioorganic and Medicinal Chemistry, 2013, 21, 5339-5354.	3.0	20
131	3-Aroylmethylene-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-ones as Potent Nrf2/ARE Inducers in Human Cancer Cells and AOM-DSS Treated Mice. Journal of Medicinal Chemistry, 2013, 56, 7925-7938.	6.4	40
132	Effective Screening Strategy Using Ensembled Pharmacophore Models Combined with Cascade Docking: Application to p53-MDM2 Interaction Inhibitors. Journal of Chemical Information and Modeling, 2013, 53, 2715-2729.	5.4	23
133	Indenoisoquinoline derivatives as topoisomerase I inhibitors that suppress angiogenesis by affecting the HIF signaling pathway. Biomedicine and Pharmacotherapy, 2013, 67, 715-722.	5.6	6
134	Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 2974-2978.	2.2	19
135	Pharmacophoreâ€Based Drug Design and Biological Evaluation of Novel ABCB1 Inhibitors. Chemical Biology and Drug Design, 2013, 81, 349-358.	3.2	5
136	Synthesis and antibacterial evaluation of a novel series of 10-hydroxyl ketolide derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3452-3457.	2.2	7
137	Synthesis and Evaluation of Gambogic Acid Derivatives as Antitumor Agents. Part III. Chemistry and Biodiversity, 2013, 10, 73-85.	2.1	14
138	Identification, Design and Bio-Evaluation of Novel Hsp90 Inhibitors by Ligand-Based Virtual Screening. PLoS ONE, 2013, 8, e59315.	2.5	17
139	Insight into the Intermolecular Recognition Mechanism between Keap1 and IKKÎ² Combining Homology Modelling, Protein-Protein Docking, Molecular Dynamics Simulations and Virtual Alanine Mutation. PLoS ONE, 2013, 8, e75076.	2.5	42
140	LYG-202 Augments Tumor Necrosis Factor-Î±-Induced Apoptosis via Attenuating Casein Kinase 2-Dependent Nuclear Factor-ÎºB Pathway in HepG2 Cells. Molecular Pharmacology, 2012, 82, 958-971.	2.3	11
141	Synthesis and evaluation of novel aza-caged Garcinia xanthones. Organic and Biomolecular Chemistry, 2012, 10, 3288.	2.8	22
142	Studies on Chemicalâ€Structure Modification and Structureï£¿Activity Relationship of Gambogic Acid Derivatives at Carbon(34). Chemistry and Biodiversity, 2012, 9, 2295-2308.	2.1	7
143	Key Role of Nuclear Factor-ÎºB in the Cellular Pharmacokinetics of Adriamycin in MCF-7/Adr Cells: The Potential Mechanism for Synergy with 20(S)-Ginsenoside Rh2. Drug Metabolism and Disposition, 2012, 40, 1900-1908.	3.3	36
144	Studies on Chemical Structure Modification and Structureï£¿Activity Relationship of Derivatives of Gambogic Acid at C(39). Chemistry and Biodiversity, 2012, 9, 1579-1590.	2.1	12

#	Article	IF	Citations
145	Synthesis and Antiâ€tumor Evaluation of Novel Câ€37 Modified Derivatives of Gambogic Acid. Chinese Journal of Chemistry, 2012, 30, 1083-1091.	4.9	9
146	Novel Dualâ€Siteâ€Binding Neuraminidase Inhibitor from Virtual Screening by Pharmacophore and Molecular Dynamics Methods. Chinese Journal of Chemistry, 2012, 30, 1735-1740.	4.9	3
147	Studies on gambogic acid (IV): Exploring structureâ€“activity relationship with ÎºB kinase-beta (IKKÎ²). European Journal of Medicinal Chemistry, 2012, 51, 110-123.	5.5	21
148	Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. Journal of Molecular Modeling, 2012, 18, 1023-1036.	1.8	34
149	Synthesis and Bioevaluation of Gambogic Acid Derivatives as Antitumor Agents. Chinese Journal of Organic Chemistry, 2012, 32, 1450.	1.3	1
150	Combination of pharmacophore model development and binding mode analyses: Identification of ligand features essential for ÎºB kinase-beta (IKKÎ²) inhibitors and virtual screening based on it. European Journal of Medicinal Chemistry, 2011, 46, 3942-3952.	5.5	13
151	Total synthesis of aldehyde-containing Garcinia natural products isomorellin and gaudichaudione A. Tetrahedron, 2011, 67, 4774-4779.	1.9	13
152	Structureâ€Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors. Molecular Informatics, 2011, 30, 579-592.	2.5	9
153	Docking Study and Threeâ€Dimensional Quantitative Structureâ€Activity Relationship (3Dâ€QSAR) Analyses and Novel Molecular Design of a Series of 4â€Aminoquinazolines as Inhibitors of Aurora B Kinase. Chinese Journal of Chemistry, 2011, 29, 1785-1799.	4.9	10
154	Pharmacophore Modeling and in Silico Screening Studies to Design Potential KDR Kinase Inhibitors. Chinese Journal of Chemistry, 2011, 29, 1107-1113.	4.9	0
155	More than a Leaving Group: N â€Phenyltrifluoroacetimidate as a Remote Directing Group for Highly Îâ€Selective 1,2â€cis Glycosylation. Angewandte Chemie, 0, , .	2.0	1
156	Discovery of tryptophanâ€tetrahydroisoquinoline derivatives as multifunctional agents for treatment of Alzheimer's disease. Chinese Journal of Chemistry, 0, , .	4.9	2